Tekla Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Tekla Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,109	Closed	-$61K	–	192
2017 Q4	$61K	Hold	1,109	–	–	﹤0.01%	160
2017 Q3	$47K	Hold	1,109	–	–	﹤0.01%	152
2017 Q2	$47K	Hold	1,109	–	–	﹤0.01%	143
2017 Q1	$62K	Hold	1,109	–	–	﹤0.01%	138
2016 Q4	$42K	Hold	1,109	–	–	﹤0.01%	142
2016 Q3	$44K	Hold	1,109	–	–	﹤0.01%	141
2016 Q2	$80K	Hold	1,109	–	–	﹤0.01%	155
2016 Q1	$89K	Hold	1,109	–	–	﹤0.01%	139
2015 Q4	$84K	Hold	1,109	–	–	﹤0.01%	132
2015 Q3	$425K	Hold	1,109	–	–	0.02%	157
2015 Q2	$461K	Hold	1,109	–	–	0.02%	112
2015 Q1	$527K	Sell	1,109 -1,109	-50%	-$526K	0.02%	113
2014 Q4	$821K	Buy	+2,218	New	+$572K	0.04%	88

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Tekla Capital Management's LRMR Position: Q1 2018 in Review

Tekla Capital Management sold out of Larimar Therapeutics (LRMR) in Q1 2018, closing a stake of 1,109 shares — an estimated $61K sold.

Tekla Capital Management first reported a position in LRMR in Q4 2014 and held it in 13 quarters. The position peaked at $821K in Q4 2014. 61 funds tracked by Wall St. Rank hold LRMR as of Q1 2018.

Tekla Capital Management reported no remaining Larimar Therapeutics position as of Q1 2018 after selling out during the quarter.
Tekla Capital Management sold 1,109 Larimar Therapeutics shares in Q1 2018, an estimated $61K.
Tekla Capital Management first reported a position in Larimar Therapeutics in Q4 2014 and held it in 13 quarters.
Tekla Capital Management's Larimar Therapeutics position peaked at $821K in Q4 2014.
61 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2018.

Based on Tekla Capital Management's 13F filing for Q1 2018, filed 14 May 2018.